Market capitalization | $10.09b |
Enterprise Value | $7.94b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.95 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-529.05m |
Free Cash Flow (TTM) Free Cash Flow | $-616.24m |
Cash position | $2.18b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
11 Analysts have issued a Vaxcyte Inc forecast:
11 Analysts have issued a Vaxcyte Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -14 -14 |
47%
47%
|
|
EBITDA | -515 -515 |
58%
58%
|
EBIT (Operating Income) EBIT | -529 -529 |
58%
58%
|
Net Profit | -508 -508 |
69%
69%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.
Head office | United States |
CEO | Grant Pickering |
Employees | 254 |
Founded | 2013 |
Website | www.vaxcyte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.